22 results on '"Veggia, Barbara"'
Search Results
2. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens
- Author
-
Marignani, Massimo, Mangone, Manuela, Cox, M. Christina, Angeletti, Stefano, Veggia, Barbara, Ferrari, Antonella, di Fonzo, Michela, Begini, Paola, Gigante, Elia, Laverde, Giacinto, Aloe-Spiriti, Antonietta, Monarca, Bruno, and Fave, Gianfranco Delle
- Published
- 2011
- Full Text
- View/download PDF
3. Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
- Author
-
Cox, Christina M., Marignani, Massimo, Veggia, Barbara, Angeletti, Stefano, Leone, Francesco, Cipriani, Paola, Gallina, Sara, Delle Fave, Gianfranco, Aloe-Spiriti, Antonietta M., and Monarca, Bruno
- Published
- 2009
- Full Text
- View/download PDF
4. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma
- Author
-
Christina Cox, M., Nofroni, Italo, Laverde, Giacinto, Ferrari, Antonella, Amodeo, Rachele, Tatarelli, Caterina, Saltarelli, Francesca, Veggia, Barbara, Aloe-Spiriti, M. Antonietta, Ruco, Luigi, and Monarca, Bruno
- Published
- 2008
5. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study
- Author
-
Del Principe, Maria Ilaria, Dragonetti, Giulia, Verga, Luisa, Candoni, Anna, Marchesi, Francesco, Cattaneo, Chiara, Delia, Mario, Potenza, Leonardo, Farina, Francesca, Ballanti, Stelvio, Decembrino, Nunzia, Castagnola, Carlo, Nadali, Gianpaolo, Fanci, Rosa, Orciulo, Enrico, Veggia, Barbara, Offidani, Massimo, Melillo, Lorella, Manetta, Sara, Tumbarello, Mario, Venditti, Adriano, Busca, Alessandro, Aversa, Franco, Pagano, Livio, Picardi, M, Della Pepa, R, Ferrari, A, Piedimonte, M, Fracchiolla, Ns, Sciumè, M, Lessi, F, Prezioso, L, Spolzino, A, Rambaldi, B, Russo, D, Maracci, L, di Ematologia, C, Sarlo, C, Annibali, O, Cefalo, M, Zizzari, A, Di Blasi, R, di Ematologia, I, Zama, D, Mancini, V, Salutari, P, Cesaro, S, Chiara Tisi, M, Garzia, Mg, Vacca, A, Dargenio, M, Invernizzi, R, Perruccio, K, Mitra, Me, Quinto, Am, Chierichini, A, and Spadea, A.
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,Antifungal Agents ,AML, SEIFEM, Invasive Aspergillosis, consolidation therapy, antifumgal prophylaxis, antifungal therapy ,030106 microbiology ,SEIFEM ,antifumgal prophylaxis ,Comorbidity ,Aspergillosis ,03 medical and health sciences ,0302 clinical medicine ,AML ,Risk Factors ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,Prospective cohort study ,Aged ,Pharmacology ,business.industry ,Incidence (epidemiology) ,Mortality rate ,Consolidation Chemotherapy ,Induction Chemotherapy ,Middle Aged ,medicine.disease ,antifungal therapy ,Leukemia, Myeloid, Acute ,Infectious Diseases ,Number needed to treat ,Cytarabine ,Invasive Aspergillosis ,Female ,business ,consolidation therapy ,Settore MED/15 - Malattie del Sangue ,Invasive Fungal Infections ,medicine.drug - Abstract
Background We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy. Methods Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and 2015, were retrospectively collected in a multicentre Italian study. Results Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P = 0.01). Number-needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P = 0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age ≥60 years (OR = 12.46, 95% CI = 1.13-136.73; P = 0.03) and high-dose cytarabine treatment (OR = 10.56, 95% CI = 1.95-116.74; P = 0.04) independently affected outcome. Conclusions In our experience, AP appears to prevent IA from occurring during consolidation. However, although the incidence of IA was low, mortality was not negligible among older patients. Further prospective studies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data and to identify subsets of individuals who may require AP.
- Published
- 2019
6. Fungaemia in haematological malignancies: SEIFEM-2015 survey
- Author
-
Criscuolo, Marianna, Marchesi, Francesco, Candoni, Anna, Cattaneo, Chiara, Nosari, Annamaria, Veggia, Barbara, Verga, Luisa, Fracchiolla, Nicola, Vianelli, Nicola, Del Principe, Maria Ilaria, Picardi, Marco, Tumbarello, Mario, Aversa, Franco, Busca, Alessandro, Pagano, Livio, Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio (ORCID:0000-0001-8287-928X), Criscuolo, Marianna, Marchesi, Francesco, Candoni, Anna, Cattaneo, Chiara, Nosari, Annamaria, Veggia, Barbara, Verga, Luisa, Fracchiolla, Nicola, Vianelli, Nicola, Del Principe, Maria Ilaria, Picardi, Marco, Tumbarello, Mario, Aversa, Franco, Busca, Alessandro, Pagano, Livio, Tumbarello, Mario (ORCID:0000-0002-9519-8552), and Pagano, Livio (ORCID:0000-0001-8287-928X)
- Abstract
BACKGROUND: Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with haematological malignancies (HMs), in which a documented fungaemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 paediatric Italian Hematology Departments. METHODS: During the study period, we recorded 215 fungal bloodstream infections (BSI). Microbiological analyses documented that BSI was due to moulds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). RESULTS: Mortality rates were 70% and 39% for mould and yeast infections, respectively. Infection was the main cause of death in 53% of the mould and 18% of the yeast groups. At the multivariate analysis, ECOG ≥ 2 and septic shock were significantly associated with increased mortality, and removal of central venous catheter (CVC) survival was found to be protective. When considering patients with candidemia only, ECOG ≥ 2 and removal of CVC were statistically associated with overall mortality. CONCLUSIONS: Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungaemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach.
- Published
- 2019
7. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria
- Author
-
Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., Delia, M., Ballanti, S., Marchesi, F., Mancini, V., Orciuolo, E., Cesaro, S., Prezioso, L., Fanci, R., Nadali, G., Chierichini, A., Facchini, L., Picardi, M., Malagola, M., Orlando, V., Trecarichi, E. M., Tumbarello, M., Aversa, F., Rossi, G., Pagano, L., Passi, Angela, Gramegna, Doriana, Russo, Domenico, Lazzarotto, Davide, Rotilio, Domenico, De Paolis, Maria Rosaria, Simonetti, Edoardo, Innocente, Maria Alessandra, Spadea, Antonio, Mazziotta, Francesco, Pegoraro, Anna, Spolzino, Angelica, Turri, Gloria, Veggia, Barbara, Tumbarello, M. (ORCID:0000-0002-9519-8552), Pagano, L. (ORCID:0000-0001-8287-928X), Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., Delia, M., Ballanti, S., Marchesi, F., Mancini, V., Orciuolo, E., Cesaro, S., Prezioso, L., Fanci, R., Nadali, G., Chierichini, A., Facchini, L., Picardi, M., Malagola, M., Orlando, V., Trecarichi, E. M., Tumbarello, M., Aversa, F., Rossi, G., Pagano, L., Passi, Angela, Gramegna, Doriana, Russo, Domenico, Lazzarotto, Davide, Rotilio, Domenico, De Paolis, Maria Rosaria, Simonetti, Edoardo, Innocente, Maria Alessandra, Spadea, Antonio, Mazziotta, Francesco, Pegoraro, Anna, Spolzino, Angelica, Turri, Gloria, Veggia, Barbara, Tumbarello, M. (ORCID:0000-0002-9519-8552), and Pagano, L. (ORCID:0000-0001-8287-928X)
- Abstract
Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All patients showing MDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE. In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%). The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of colonization.
- Published
- 2018
8. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), Tumbarello, Mario (ORCID:0000-0002-9519-8552), Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, Tumbarello, Mario, Pagano, Livio (ORCID:0000-0001-8287-928X), and Tumbarello, Mario (ORCID:0000-0002-9519-8552)
- Abstract
na
- Published
- 2017
9. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Pagano, Livio, primary, Dragonetti, Giulia, additional, Cattaneo, Chiara, additional, Marchesi, Francesco, additional, Veggia, Barbara, additional, Busca, Alessandro, additional, Candoni, Anna, additional, Prezioso, Lucia, additional, Criscuolo, Marianna, additional, Cesaro, Simone, additional, Delia, Mario, additional, Fanci, Rosa, additional, Stanzani, Marta, additional, Ferrari, Antonella, additional, Martino, Bruno, additional, Melillo, Lorella, additional, Nadali, Gianpaolo, additional, Simonetti, Edoardo, additional, Ballanti, Stelvio, additional, Picardi, Marco, additional, Castagnola, Carlo, additional, Decembrino, Nunzia, additional, Gazzola, Marco, additional, Fracchiolla, Nicola Stefano, additional, Mancini, Valentina, additional, Nosari, Annamaria, additional, Principe, Maria Ilaria Del, additional, Aversa, Franco, additional, and Tumbarello, Mario, additional
- Published
- 2017
- Full Text
- View/download PDF
10. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
- Author
-
Principe, Maria Ilaria Del, Dragonetti, Giulia, Verga, Luisa, Candoni, Anna, Marchesi, Francesco, Cattaneo, Chiara, Delia, Mario, Potenza, Leonardo, Farina, Francesca, Ballanti, Stelvio, Decembrino, Nunzia, Castagnola, Carlo, Nadali, Gianpaolo, Fanci, Rosa, Orciulo, Enrico, Veggia, Barbara, Offidani, Massimo, Melillo, Lorella, Manetta, Sara, and Tumbarello, Mario
- Subjects
PREVENTIVE medicine ,ANTIFUNGAL agents ,CANCER chemotherapy ,ACUTE myeloid leukemia ,MYELOID leukemia - Abstract
Background: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy.Methods: Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and 2015, were retrospectively collected in a multicentre Italian study.Results: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P = 0.01). Number-needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P = 0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age ≥60 years (OR = 12.46, 95% CI = 1.13-136.73; P = 0.03) and high-dose cytarabine treatment (OR = 10.56, 95% CI = 1.95-116.74; P = 0.04) independently affected outcome.Conclusions: In our experience, AP appears to prevent IA from occurring during consolidation. However, although the incidence of IA was low, mortality was not negligible among older patients. Further prospective studies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data and to identify subsets of individuals who may require AP. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. Quality-of-Life Monitoring During Hematopoietic Stem Cell Transplantation: Observations and a Suggestion From the Rome Transplant Network Quality of Life Working Party
- Author
-
Tendas, Andrea, primary, Pignatelli, Adriana Concetta, additional, Sollazzo, Fabio, additional, Veggia, Barbara, additional, Conte, Esmeralda, additional, D'Apolito, Antonella, additional, Di Veroli, Ambra, additional, Molinari, Veronica, additional, Mauroni, Mariarita, additional, Annibali, Ombretta, additional, Pilozzi, Vittoria, additional, Cacciaraichi, Stella, additional, Viggiani, Caterina, additional, Niscola, Pasquale, additional, de Fabritiis, Paolo, additional, and Arcese, William, additional
- Published
- 2013
- Full Text
- View/download PDF
12. Successful Autologous Peripheral Blood Stem Cell Transplantation in 3 Women with POEMS Syndrome: A Single Centre Experience
- Author
-
Antolino, Giusy, primary, Antonini, Giovanni, additional, Ferrari, Antonella, additional, La Verde, Giacinto, additional, Porrini, Raffaele, additional, Saltarelli, Francesca, additional, Conte, Esmeralda, additional, Veggia, Barbara, additional, Naso, Virginia, additional, Latino, Pamela, additional, Arcese, William, additional, and Montefusco, Enrico, additional
- Published
- 2011
- Full Text
- View/download PDF
13. Antifungal Prophilaxis with Low Dose Amphotericin B Lipid Complex In Patients with Acute Myeloid Leukaemia: A Single Centre Experience
- Author
-
Veggia, Barbara, primary, Saltarelli, Francesca, additional, Montefusco, Enrico, additional, Conte, Esmeralda, additional, Antolino, Giusy, additional, Porrini, Raffaele, additional, Monarca, Bruno, additional, and Ferrari, Antonella, additional
- Published
- 2011
- Full Text
- View/download PDF
14. Is management with lamivudine always the appropriate choice for HBV patients with onco-hematologic diseases?
- Author
-
Cox, M. Christina, primary, Marignani, Massimo, additional, Veggia, Barbara, additional, Angeletti, Stefano, additional, Leone, Francesco, additional, Cipriani, Paola, additional, Gallina, Sara, additional, Fave, Gianfranco Delle, additional, Aloe-Spiriti, M. Antonietta, additional, and Monarca, Bruno, additional
- Published
- 2008
- Full Text
- View/download PDF
15. Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma.
- Author
-
Cox, M. Christina, Nofroni, Italo, Laverde, Giacinto, Ferrari, Antonella, Amodeo, Rachele, Tatarelli, Caterina, Saltarelli, Francesca, Veggia, Barbara, Aloe-Spiriti, M. Antonietta, Ruco, Luigi, and Monarca, Bruno
- Subjects
LETTERS to the editor ,LYMPHOMAS - Abstract
A letter to the editor is presented that discusses absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma.
- Published
- 2008
- Full Text
- View/download PDF
16. Erythema Annulare Centrifugum Associated with Mantle B-cell Non-Hodgkin's Lymphoma.
- Author
-
Carlesimo, Marta, Fidanza, Laura, Mari, Elena, Pranted, Guglielmo, Cacchi, Claudio, Veggia, Barbara, Cox, Maria Cristina, and Camplone, Germana
- Subjects
LETTERS to the editor ,ERYTHEMA - Abstract
A letter to the editor is presented regarding figurate erythemas characterized as erythema annulare centrifugum, necrolytic migratory erythma and erythma gyratum repens.
- Published
- 2009
- Full Text
- View/download PDF
17. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey
- Author
-
Luisa Verga, Chiara Cattaneo, Monica Piedimonte, Rosa Fanci, Gianpaolo Nadali, Mariagrazia Garzia, Enrico Orciulo, Barbara Veggia, Angelica Spolzino, Nicola Toschi, Federica Lessi, Daniele Zama, Nicola Stefano Fracchiolla, Leonardo Potenza, Maria Chiara Tisi, Alessandro Busca, Mario Delia, Maria Ilaria Del Principe, Lucia Prezioso, Carlo Castagnola, Nunzia Decembrino, Valentina Mancini, Allegra Conti, Giulia Dragonetti, Francesco Marchesi, Sara Manetta, Anna Candoni, Michelina Dargenio, Lorella Melillo, Livio Pagano, Marco Picardi, Stelvio Ballanti, Domenico Russo, Del Principe, Maria Ilaria, Dragonetti, Giulia, Conti, Allegra, Verga, Luisa, Ballanti, Stelvio, Fanci, Rosa, Candoni, Anna, Marchesi, Francesco, Cattaneo, Chiara, Lessi, Federica, Fracchiolla, Nicola, Spolzino, Angelica, Prezioso, Lucia, Delia, Mario, Potenza, Leonardo, Decembrino, Nunzia, Castagnola, Carlo, Nadali, Gianpaolo, Picardi, Marco, Zama, Daniele, Orciulo, Enrico, Veggia, Barbara, Garzia, Mariagrazia, Dargenio, Michelina, Melillo, Lorella, Manetta, Sara, Russo, Domenico, Mancini, Valentina, Piedimonte, Monica, Tisi, Maria Chiara, Toschi, Nicola, Busca, Alessandro, and Pagano, Livio
- Subjects
Myeloid ,medicine.medical_specialty ,Posaconazole ,Antifungal Agents ,breakthrough infection ,Salvage treatment ,salvage chemotherapy ,Dermatology ,Acute ,Aspergillosis ,Gastroenterology ,invasive aspergillosi ,Refractory ,antifungal prophylaxis ,Internal medicine ,medicine ,Mucositis ,refractory acute myeloid leukaemia ,antifungal prophylaxi ,Humans ,Prospective cohort study ,Retrospective Studies ,invasive aspergillosis ,Leukemia ,business.industry ,Incidence (epidemiology) ,breakthrough infections ,Myeloid leukemia ,General Medicine ,medicine.disease ,Settore MED/15 ,posaconazole ,antifungal therapy ,relapsed acute myeloid leukaemia ,Leukemia, Myeloid, Acute ,Settore MED/15 - MALATTIE DEL SANGUE ,Infectious Diseases ,business ,Invasive Fungal Infections ,medicine.drug - Abstract
Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective 'SEIFEM 2016-B' study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large 'real life' series of patient with R/R AML submitted to salvage chemotherapy. Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p 
- Published
- 2022
18. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria
- Author
-
Lucia Prezioso, Michele Malagola, Maria Alessandra Innocente, Edoardo Simonetti, Livio Pagano, Angelica Spolzino, R Di Blasi, Barbara Veggia, Angela Passi, Luca Facchini, Simone Cesaro, Gianpaolo Nadali, Doriana Gramegna, Marco Picardi, Gloria Turri, Antonio Spadea, Enrico Orciuolo, Stelvio Ballanti, Anna Candoni, Cristina Skert, Davide Lazzarotto, Enrico Maria Trecarichi, Francesco Marchesi, Vincenza Orlando, Rosa Fanci, Mario Delia, Maria Rosaria De Paolis, Domenico Russo, Bruno Martino, Valentina Mancini, N. Di Renzo, Anna Chierichini, Giorgio Rossi, Anna Pegoraro, Mario Tumbarello, Cristina Cattaneo, Francesco Mazziotta, Domenico Rotilio, Franco Aversa, Cattaneo, C., Di Blasi, R., Skert, C., Candoni, A., Martino, B., Di Renzo, N., Delia, M., Ballanti, S., Marchesi, F., Mancini, V., Orciuolo, E., Cesaro, S., Prezioso, L., Fanci, R., Nadali, G., Chierichini, A., Facchini, L., Picardi, M., Malagola, M., Orlando, V., Trecarichi, E. M., Tumbarello, M., Aversa, F., Rossi, G., Pagano, L., Passi, Angela, Gramegna, Doriana, Russo, Domenico, Lazzarotto, Davide, Rotilio, Domenico, De Paolis, Maria Rosaria, Simonetti, Edoardo, Innocente, Maria Alessandra, Spadea, Antonio, Mazziotta, Francesco, Pegoraro, Anna, Spolzino, Angelica, Turri, Gloria, and Veggia, Barbara
- Subjects
0301 basic medicine ,Male ,Colonization ,Multidrug-resistant bacteria ,Antibiotics ,Drug Resistance ,Bacteremia ,Bloodstream infections ,Haematologic patients ,Adolescent ,Adult ,Aged ,Aged, 80 and over ,Bacterial Infections ,Catheter-Related Infections ,Child ,Child, Preschool ,Female ,Hematologic Neoplasms ,Humans ,Infant ,Infant, Newborn ,Middle Aged ,Young Adult ,Drug Resistance, Multiple, Bacterial ,0302 clinical medicine ,80 and over ,030212 general & internal medicine ,Young adult ,Pathogen ,Hematology ,Incidence (epidemiology) ,Bacterial ,General Medicine ,Bloodstream infections, haematological cancer patients, multidrug-resistant bacteria ,Haematologic patient ,Multiple ,Human ,medicine.medical_specialty ,medicine.drug_class ,030106 microbiology ,Neutropenia ,Bloodstream infection ,Bacterial Infection ,03 medical and health sciences ,Internal medicine ,medicine ,Preschool ,Hematologic Neoplasm ,Catheter-Related Infection ,business.industry ,biochemical phenomena, metabolism, and nutrition ,medicine.disease ,Newborn ,bacterial infections and mycoses ,business - Abstract
Infections by multidrug-resistant (MDR) bacteria are a worrisome phenomenon in hematological patients. Data on the incidence of MDR colonization and related bloodstream infections (BSIs) in haematological patients are scarce. A multicentric prospective observational study was planned in 18 haematological institutions during a 6-month period. All patients showing MDR rectal colonization as well as occurrence of BSI at admission were recorded. One-hundred forty-four patients with MDR colonization were observed (6.5% of 2226 admissions). Extended spectrum beta-lactamase (ESBL)-producing (ESBL-P) enterobacteria were observed in 64/144 patients, carbapenem-resistant (CR) Gram-negative bacteria in 85/144 and vancomycin-resistant enterococci (VREs) in 9/144. Overall, 37 MDR-colonized patients (25.7%) developed at least one BSI; 23 of them (62.2%, 16% of the whole series) developed BSI by the same pathogen (MDRrel BSI), with a rate of 15.6% (10/64) for ESBL-P enterobacteria, 14.1% (12/85) for CR Gram-negative bacteria and 11.1% (1/9) for VRE. In 20/23 cases, MDRrel BSI occurred during neutropenia. After a median follow-up of 80 days, 18 patients died (12.5%). The 3-month overall survival was significantly lower for patients colonized with CR Gram-negative bacteria (83.6%) and VRE (77.8%) in comparison with those colonized with ESBL-P enterobacteria (96.8%). CR-rel BSI and the presence of a urinary catheter were independent predictors of mortality. MDR rectal colonization occurs in 6.5% of haematological inpatients and predicts a 16% probability of MDRrel BSI, particularly during neutropenia, as well as a higher probability of unfavourable outcomes in CR-rel BSIs. Tailored empiric antibiotic treatment should be decided on the basis of colonization.
- Published
- 2018
19. Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report
- Author
-
Edoardo Simonetti, Mario Tumbarello, Rosa Fanci, Carlo Castagnola, Nunzia Decembrino, Mario Delia, Antonella Ferrari, Lorella Ma Melillo, Franco Aversa, Chiara Cattaneo, Bruno Martino, Giulia Dragonetti, Annamaria Nosari, Lucia Prezioso, Maria Ilaria Del Principe, Marta Stanzani, Nicola Stefano Fracchiolla, Stelvio Ballanti, Gianpaolo Nadali, Francesco Marchesi, Simone Cesaro, Barbara Veggia, Marco Picardi, Anna Candoni, Alessandro Busca, Marco Gazzola, Livio Pagano, Valentina Mancini, Marianna Criscuolo, Pagano, Livio, Dragonetti, Giulia, Cattaneo, Chiara, Marchesi, Francesco, Veggia, Barbara, Busca, Alessandro, Candoni, Anna, Prezioso, Lucia, Criscuolo, Marianna, Cesaro, Simone, Delia, Mario, Fanci, Rosa, Stanzani, Marta, Ferrari, Antonella, Martino, Bruno, Melillo, Lorella, Nadali, Gianpaolo, Simonetti, Edoardo, Ballanti, Stelvio, Picardi, Marco, Castagnola, Carlo, Decembrino, Nunzia, Gazzola, Marco, Fracchiolla, Nicola Stefano, Mancini, Valentina, Nosari, Annamaria, Principe, Maria Ilaria Del, Aversa, Franco, and Tumbarello, Mario
- Subjects
0301 basic medicine ,Antifungal ,medicine.medical_specialty ,Antifungal Agents ,medicine.drug_class ,medicine.medical_treatment ,030106 microbiology ,Hematopoietic stem cell transplantation ,03 medical and health sciences ,Internal medicine ,hemic and lymphatic diseases ,Candidemia ,Hematologic Neoplasms ,Hematopoietic Stem Cell Transplantation ,Humans ,Incidence ,Retrospective Studies ,Epidemiology ,medicine ,In patient ,Intensive care medicine ,Online Only Articles ,skin and connective tissue diseases ,Candida infection, hematological malignacy, adult, pediatric, mortality ,Candidemia, hematologic malignancies ,Candida infection ,business.industry ,Incidence (epidemiology) ,adult ,Retrospective cohort study ,Hematology ,equipment and supplies ,bacterial infections and mycoses ,Settore MED/15 ,mortality ,Settore MED/15 - MALATTIE DEL SANGUE ,surgical procedures, operative ,pediatric ,Multicenter study ,hematological malignacy ,Conventional chemotherapy ,sense organs ,business - Abstract
The epidemiology of invasive fungal infections (IFI) among patients with hematologic malignancies who are undergoing either conventional chemotherapy or hematopoietic stem cell transplantation (HSCT) is changing due to the introduction of new, effective antifungal agents for both prophylaxis and
- Published
- 2017
20. Fungaemia in haematological malignancies: SEIFEM-2015 survey
- Author
-
Criscuolo, M., Marchesi, F., Candoni, A., Cattaneo, C., Nosari, A., Veggia, B., Verga, L., Fracchiolla, N., Vianelli, N., Del Principe, M. I., Picardi, M., Tumbarello, M., Aversa, F., Busca, A., Pagano, L., Dragonetti, G., Ballanti, S., Delia, M., Nadali, G., Sciume, M., Castagnola, C., Ferrari, A., Mancini, V., Decembrino, N., Spolzino, A., Iovino, L., Martino, B., Vacca, A., Calore, E., Fanci, R., Lessi, F., Vallero, S., Zama, D., Cesaro, S., De Paolis, M. R., Facchini, L., Muggeo, P., Offidani, M., Perruccio, K., Russo, D., Criscuolo M, Marchesi F, Candoni A, Cattaneo C, Nosari A, Veggia B, Verga L, Fracchiolla N, Vianelli N, Del Principe MI, Picardi M, Tumbarello M, Aversa F, Busca A, Pagano L, SEIFEM Group: Giulia Dragonetti, Stelvio Ballanti, Mario Delia, Gianpaolo Nadali, Sciumè M, Castagnola C, Ferrari A, Mancini V, Decembrino N, Spolzino A, Iovino L, Martino B, Vacca A, Calore E, Fanci R, Lessi F, Vallero S, Zama D, Cesaro S, De Paolis M, Facchini L, Muggeo P, Offidani M, Perruccio K, Russo D., Criscuolo, Marianna, Marchesi, Francesco, Candoni, Anna, Cattaneo, Chiara, Nosari, Annamaria, Veggia, Barbara, Verga, Luisa, Fracchiolla, Nicola, Vianelli, Nicola, Del Principe, Maria Ilaria, Picardi, Marco, Tumbarello, Mario, Aversa, Franco, Busca, Alessandro, and Pagano, Livio
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Clinical Biochemistry ,Prevalence ,030204 cardiovascular system & hematology ,Biochemistry ,Young Adult ,03 medical and health sciences ,acute leukaemias ,candidemia ,fungaemia ,0302 clinical medicine ,Risk Factors ,Yeasts ,Internal medicine ,acute leukemias ,Epidemiology ,Fungemia, Hematological malignancies ,medicine ,Aged ,Candidemia ,Child ,Female ,Fungemia ,Hematologic Neoplasms ,Humans ,Italy ,Middle Aged ,Prognosis ,Retrospective Studies ,acute leukemia ,030212 general & internal medicine ,Cause of death ,Hematology ,business.industry ,Septic shock ,Mortality rate ,General Medicine ,bacterial infections and mycoses ,medicine.disease ,Settore MED/15 - MALATTIE DEL SANGUE ,fungemia ,business ,Central venous catheter - Abstract
BACKGROUND: Fungal infections are still a relevant challenge for clinicians involved in the cure of patients with cancer. We retrospectively reviewed charts of hospitalized patients with hematological malignancies (HMs), in which a documented fungemia was diagnosed between January 2011 and December 2015 at 28 adult and 6 pediatric Italian Hematology Departments. METHODS: During the study period we recorded 215 fungal blood stream infections (BSI). Microbiological analyses documented that BSI was due to molds in 17 patients (8%) and yeasts in 198 patients (92%), being Candida spp identified in 174 patients (81%). RESULTS: Mortality rates were 70% and 39% for mold and yeast infections, respectively. Infection was the main cause of death in 53% of the mold and 18% of the yeast groups. At the multivariate analysis, ECOG ≥2 and septic shock were significantly associated with increased mortality, and removal of CVC survival was found to be protective. When considering patients with candidemia only, ECOG >2 and removal of CVC were statistically associated with overall mortality. CONCLUSIONS: Although candidemia represents a group of BSI with a good prognosis, its risk factors largely overlap with those identified for all fungemias, even though the candidemia-related mortality is lower when compared to other fungal BSI. Management of fungal BSI is still a complex issue, in which both patients and disease characteristics should be focused to address a personalized approach. This article is protected by copyright. All rights reserved.
- Published
- 2019
21. Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey.
- Author
-
Del Principe MI, Dragonetti G, Conti A, Verga L, Ballanti S, Fanci R, Candoni A, Marchesi F, Cattaneo C, Lessi F, Fracchiolla N, Spolzino A, Prezioso L, Delia M, Potenza L, Decembrino N, Castagnola C, Nadali G, Picardi M, Zama D, Orciulo E, Veggia B, Garzia M, Dargenio M, Melillo L, Manetta S, Russo D, Mancini V, Piedimonte M, Tisi MC, Toschi N, Busca A, and Pagano L
- Subjects
- Humans, Retrospective Studies, Antifungal Agents therapeutic use, Aspergillosis drug therapy, Aspergillosis epidemiology, Invasive Fungal Infections drug therapy, Invasive Fungal Infections epidemiology, Leukemia, Myeloid, Acute complications, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute microbiology
- Abstract
Background: In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP). The aims of this multicentre retrospective 'SEIFEM 2016-B' study were as follows: (1) to evaluate the current rate and the outcome of proven/probable IA and (2) to assess the efficacy of AP, in a large 'real life' series of patient with R/R AML submitted to salvage chemotherapy., Results: Of 2250 R/R AML patients, a total of 74 cases of IA (5.1%) were recorded as follows: 10 (0.7%) proven and 64 (4.3%) probable. Information about AP were available in 73/74 (99%) patients. Fifty-eight (79%) breakthrough infections occurred, mainly during AP with posaconazole [25 (43%)]. The patients who received AP during salvage chemotherapy showed a benefit from antifungal therapy (AT) than patients who did not received AP [43 (86%) vs 7 (14%); p < .033]. In a multivariate analysis, AP and absence of severe mucositis had a significant favourable effect on overall response rate., Conclusion: Our data demonstrated that the incidence of IA during the salvage chemotherapy is similar to the past. Nevertheless, the attributable mortality rate (AMR) appears to be lower than that previously reported in R/R AML. Further prospective studies should be performed to confirm our preliminary observation and understand and the why a decreased AMR is reported in this setting of high-risk patients., (© 2021 Wiley-VCH GmbH.)
- Published
- 2022
- Full Text
- View/download PDF
22. 'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study.
- Author
-
Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, Delia M, Potenza L, Farina F, Ballanti S, Decembrino N, Castagnola C, Nadali G, Fanci R, Orciulo E, Veggia B, Offidani M, Melillo L, Manetta S, Tumbarello M, Venditti A, Busca A, Aversa F, and Pagano L
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aspergillosis epidemiology, Comorbidity, Consolidation Chemotherapy, Female, Humans, Induction Chemotherapy adverse effects, Invasive Fungal Infections epidemiology, Leukemia, Myeloid, Acute drug therapy, Leukemia, Myeloid, Acute epidemiology, Leukemia, Myeloid, Acute etiology, Male, Middle Aged, Risk Factors, Antifungal Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Aspergillosis etiology, Aspergillosis prevention & control, Invasive Fungal Infections etiology, Invasive Fungal Infections prevention & control, Leukemia, Myeloid, Acute complications
- Abstract
Background: We evaluated the incidence of proven/probable invasive aspergillosis (IA) and the role of antifungal prophylaxis (AP) in a 'real-life' setting of patients with AML receiving intensive consolidation therapy., Methods: Cases of IA, observed during consolidation in adult/paediatric patients with AML between 2011 and 2015, were retrospectively collected in a multicentre Italian study., Results: Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) and 13 proven (0.5%)]. IA was diagnosed in 34 of 1137 (2.9%) patients receiving no AP and in 22 of 1451 (1.5%) who were given AP (P = 0.01). Number-needed-to-treat calculation indicates that, on average, 71 patients should have received AP (instead of no AP) for one additional patient to not have IA. Initial antifungal therapy was 'pre-emptive' in 36 (64%) patients and 'targeted' in 20 (36%) patients. A good response to first-line therapy was observed in 26 (46%) patients, mainly those who received AP [16 of 22 (73%) versus 10 of 34 (29%); P = 0.001]. The overall mortality rate and the mortality rate attributable to IA by day 120 were 16% and 9%, respectively. In multivariate analysis, age ≥60 years (OR = 12.46, 95% CI = 1.13-136.73; P = 0.03) and high-dose cytarabine treatment (OR = 10.56, 95% CI = 1.95-116.74; P = 0.04) independently affected outcome., Conclusions: In our experience, AP appears to prevent IA from occurring during consolidation. However, although the incidence of IA was low, mortality was not negligible among older patients. Further prospective studies should be carried out particularly in elderly patients treated with high-dose cytarabine to confirm our data and to identify subsets of individuals who may require AP., (© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.